Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib

NCT00352742 is registered in ClinicalTrials.gov with Attenuon as lead sponsor.

NCT NCT00352742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib
Lead sponsor
Attenuon
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2006
Completion date
December 31, 2008
Enrollment
46 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma